Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
about
Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsTargeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaAnti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distributionExploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesTumor endothelial cellsCombined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapiesUse of Quantitative Dynamic Contrast-Enhanced Ultrasound to Assess Response to Antiangiogenic Therapy in Children and Adolescents With Solid Malignancies: A Pilot StudyThe antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networksA pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis.Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenograftsModeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic DrugsTumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugsDominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinibCombination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.Structural adaptation and heterogeneity of normal and tumor microvascular networks.The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinomaRandomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancerModel driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasisImproved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiationVEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-BRadiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation.Targeting multiple angiogenic pathways for the treatment of neuroblastoma.Effect of pazopanib on tumor microenvironment and liposome deliveryHyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization.The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.Contrast-enhanced sonography of malignant pediatric abdominal and pelvic solid tumors: preliminary safety and feasibility data.Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts.Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approachesThe paradoxical effect of bevacizumab in the therapy of malignant gliomas.Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.
P2860
Q26746067-77245405-0F77-4807-9FBF-3401D4C1C0D8Q26747666-12724B69-38F6-4CEA-9E29-E0DC06AD45C3Q26796955-FCA31725-A685-4035-90B1-DD5628B25597Q26828930-969EAA55-140B-4A1F-AA15-6668D5FA038DQ26995733-F0959ABF-CF06-4DF3-9283-9347D814FDDFQ28472150-124CDFA7-61F1-437A-BAB9-EA5D8833B893Q28488869-3503E026-4C1D-4088-BCBA-9E0D7669D773Q30357444-AFC77655-924E-459D-BEB6-76C3DBEDC1D1Q30409780-22C50C2F-4878-4CAB-A088-159251F29BA6Q30469815-20D36FEC-6398-47F2-8AAC-87A40979FA71Q30471456-AFCB2CE5-547E-4F40-96C0-9130D1FB9D2BQ30475052-52D88275-3E4A-44EA-A299-1E895AD5FB93Q30641737-1CA8AA36-BC2E-4EA1-81DE-C4D124411EB8Q30855619-5EE83BEB-8793-4215-BF80-5B61BC0A7A7BQ31143294-445FA63D-48CD-4579-959E-E81902267C05Q33344362-D36B4F64-41B3-4681-A7A1-E90E66F3817AQ33400232-3A5999B2-AC63-4D8A-90EA-55FD6F9FCCE7Q33438641-FF9328CC-128C-4A53-BCE3-6C2EDB40D111Q33441574-745938EA-6A66-46FD-81C0-F7DE8980591DQ33455556-08C2B0E1-A284-4383-BD64-CFFE0E872A2AQ33514437-0893E956-4D56-462B-89DC-3378CDB2BECDQ33598561-249AC3EA-5623-4EB1-B60A-1FC6188C5666Q33618582-B467CFE9-3D09-48A1-9A48-18A2229820F0Q33756489-E1EFB6E9-7423-49CD-97F4-85D52C84C87BQ33772197-C8173AF2-A0E6-430A-B164-9F639969F0BBQ33922852-DE1138E6-BE92-4ACB-B11B-86324AA4546EQ33964937-115F800A-0B6E-41CF-A5C8-833E1A6A3F47Q33976318-D3C68D63-EC5E-4587-BA6F-BE7FEDDCD9B4Q33995820-9CA35F36-40B3-4956-9A6F-5F357F032B9AQ33995832-A8CF3301-CB8B-4A32-AAFC-68771DDB30AFQ34018204-8565E967-F39C-47A9-B6C1-76793A740D1FQ34120237-A717BA93-D2A0-4471-8B85-2E0EC16E8BA0Q34122191-1751E3FE-A422-4D3E-AEB8-BE1BC1699577Q34128969-881622DC-BD2E-4FC7-B622-DF39FE935C7DQ34249349-EE4CEB8C-BA40-4CA8-A70B-A203816210C7Q34402998-B6CE02FA-774C-41F8-A7C0-AF578C775DB2Q34497997-2C41B7CF-CC78-4FCD-969D-2E092095B7BEQ34515465-31411F3C-483D-4783-98E9-6070728C2C48Q34536275-5DFA21B0-CE41-45B4-8E78-9DC45260BC47Q34682223-FD580BC7-93EE-4B9D-AFEA-FFE1EAD6B5CB
P2860
Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Bevacizumab-induced transient ...... lly administered chemotherapy.
@en
type
label
Bevacizumab-induced transient ...... lly administered chemotherapy.
@en
prefLabel
Bevacizumab-induced transient ...... lly administered chemotherapy.
@en
P2093
P921
P1476
Bevacizumab-induced transient ...... lly administered chemotherapy.
@en
P2093
Andrew M Davidoff
Catherine Y C Ng
Charles H Fraga
Clinton F Stewart
John B Hamner
M Beth McCarville
Nikolaus L Hagedorn
Paxton V Dickson
Surender Rajasekeran
Thomas L Sims
P304
P356
10.1158/1078-0432.CCR-07-0278
P407
P577
2007-07-01T00:00:00Z